TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7963709
Drug: Intermittent dideoxycytidine
Normalized name: deoxycytidine
DrugBank: 2'-Deoxycytidine (DB02594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dideoxycytidine (ddC) (0.03 mg/kg every 4 h)
Study: 3307888
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy given in a similar treatment schedule
Study: 31772064
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) therapy (60 L/min) for 15 min
Study: 31772064
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen (O2) therapy for 15 min
Study: 18419825
Drug: 5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml/kg normal saline (Ns group, n = 32)
Study: 18419825
Drug: 5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml/kg 3.5% sodium chloride (Hs group, n = 30)
Study: 18419825
Drug: 5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml/kg 5% sodium bicarbonate (Sb group, n = 32)
Study: 16768639
Drug: Risperidone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (1.5 mg/day)
Study: 22741619
Drug: Quetiapine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (200 mg/day)
Study: 11530275
Drug: Olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10 mg/day)
Study: 11053917
Drug: Calcitriol 3
Normalized name: CALCITRIOL 3MCG/GM OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 3 microg/g ointment (twice daily)
Study: 11053917
Drug: Dithranol cream
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dithranol cream (0.25-2%, once daily for 30 min)
Study: 9057430
Drug: 5-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day treatment with bismuth, metronidazole, and tetracycline
Study: 9057430
Drug: 7-day treatment
Normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day treatment with bismuth, metronidazole, and tetracycline
Study: 21718474
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g methylprednisolone for three consecutive days
Study: 11506100
Drug: 0.075 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg/kg cisatracurium
Study: 8291370
Drug: High-dose methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methyl prednisolone (HDMP) 10 mg/kg/day for 5 days i.v. (n = 10)
Study: 8291370
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 0.4 g/kg/day for 5 days (n = 10)
Study: 8291370
Drug: Conventional-dose prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose prednisone (CDP) 2 mg/kg/day for 4 weeks p.o. (n = 10)
Study: 8291370
Drug: Vincristine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine 1.5 mg/m2/week i.v. 4 doses (n = 4)
Study: 8291370
Drug: IVIG 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 0.4 g/kg/day for 5 days (n = 8)
Study: 26060122
Drug: Therapy with
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy with glycoprotein IIb/IIIa inhibitors
Study: 16815858
Drug: Everolimus 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 3.0 mg/day
Study: 17181650
Drug: Everolimus 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 3.0 mg/day with basiliximab
Study: 17181650
Drug: Everolimus 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 1.5 mg/day with basiliximab
Study: 31037562
Drug: Everolimus (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (both doses)
Study: 11920260
Drug: MP (melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP (melphalan 9 mg/m2 p.o. and prednisone 60 mg/m2 days 1-4)
Study: 7920946
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol valerate (E2-V) 4 mg/day for 28 days
Study: 1095132
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (dummy tablets)
Study: 20177421
Drug: p38 kinase
Normalized name: Kinase (enzyme-activating), uro-urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: p38 kinase inhibitor
Study: 20177421
Drug: Specific enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific enzyme inhibitors and expressed recombinant enzymes
Study: 19705093
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (training program with simple gymnastic and physiotherapeutic exercises)
Study: 10699342
Drug: Vaccine containing
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine containing recombinant MSP2 (3D7 allele), MSP1 (190LCS.T3), and RESA antigen (C terminal 771 amino acids) in Montanide ISA 720 adjuvant, administered in two doses 6 weeks apart.
Study: 10699342
Drug: Placebo (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (adjuvant emulsion), administered in two doses 6 weeks apart.
Study: 10699342
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (vaccine and placebo) were challenged with approximately 140 ring infected red cells of the 3D7 cloned line, 4 weeks after the second dose.
Study: 10699342
Drug: Vaccine and
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine and placebo groups.
Study: 9471828
Drug: Low power
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low power laser therapy (904 nm, 5 kHz, in the dose of 1 J/cm2)
Study: 9471828
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of corticosteroid infiltration and laser therapy
Study: 9471828
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Low power laser therapy)
Study: 8398330
Drug: Mitomycin-C (MMC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin-C (MMC), 20 mg/m2 intravenously one day every 6 weeks for four courses, starting before the sixth week after surgery
Study: 8398330
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no further treatment after surgery
Study: 8398330
Drug: Mitomycin-C (MMC)
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin-C (MMC) treatment
Study: 27568492
Drug: Percutaneous ilioinguinal
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous ilioinguinal nerve block with additional perineural infiltration of the ilioinguinal, iliohypogastric, genitofemoral nerves (total of 12 mL of 0.5% bupivacaine)
Study: 16105975
Drug: Continued conventional
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued conventional chemotherapy
Study: 12269674
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Iron plus folate) in the subgroup with lowest quartile of baseline haemoglobin values
Study: 7814158
Drug: Captopril (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (6.25 mg orally 15 min before thrombolysis) + Metoprolol (i.v. not later than 1 h, then orally)
Study: 7814158
Drug: Captopril (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (6.25 mg orally 15 min before thrombolysis)
Study: 2773841
Drug: Iron dextran
Normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron dextran injection at 2 months
Study: 2019922
Drug: Iron dextran
Normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron dextran injection
Study: 319140
Drug: Subcutaneous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous terbutaline (0.01 mg/kg, maximum 0.25 mg)
Study: 319140
Drug: Subcutaneous epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous epinephrine (0.01 mg/kg, maximum 0.25 mg)
Study: 10642384
Drug: MCT+CHO (0.36
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT+CHO (0.36 g tricaprin (C10:0)/kg plus 0.72 g sucrose/kg)
Study: 10642384
Drug: CHO (0.72
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (0.72 g sucrose/kg)
Study: 8851458
Drug: Oxaprozin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaprozin (1200 mg/d)
Study: 8851458
Drug: Nabumetone (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (1500 mg/d)
Study: 1510191
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (50% oxygen inhalation)
Study: 6486489
Drug: Aminophylline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (2 mg/kg intravenously) after diazepam (15 mg intravenously)
Study: 6486489
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after diazepam (15 mg intravenously)
Study: 24107737
Drug: LCI699 (aldosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699 (aldosterone synthase inhibitor)
Study: 12134255
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (ZDV, 3TC, APV)
Study: 23246635
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg IV buprenorphine
Study: 23246635
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg IV buprenorphine
Study: 23246635
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg IV buprenorphine
Study: 15327190
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (F and A)
Study: 11269574
Drug: BAY 12‐9566
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 12‐9566 400 mg
Study: 9552067
Drug: Oral granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral granisetron 2 mg
Study: 15139789
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron 32 mg
Study: 20837354
Drug: EGb 761®
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761® (240 mg once daily)
Study: 8446850
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg single dose)
Study: 3528403
Drug: MCBP (melphalan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCBP (melphalan, cyclophosphamide, and carmustine in combination)
Study: 3528403
Drug: Seq‐MCBP (sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seq‐MCBP (sequential MCBP)
Study: 3065083
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at a rate of 20 mg kg‐1 h‐1 for 5 min, reducing to 12 mg kg‐1 h‐1 for 10 min and then 6 mg kg‐1 h‐1 thereafter.
Study: 15225149
Drug: Topiramate treatment
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate treatment (adjunctive)
Study: 7684551
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (0.09U (kg BW)‐1 day‐1 sc)
Study: 3101524
Drug: Ibuprofen at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen at a dose of 2,400 mg per day
Study: 11022811
Drug: Psychosocial treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatments for cocaine dependence
Study: 27091970
Drug: Psilocybin (Psi)
Normalized name: psi-Norephedrine
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (Psi) 0.215 mg/kg
Study: 15049436
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol plus levonorgestrel (0.02 mg/0.1 mg)
Study: 2691100
Drug: High-dose steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose steroids (125 mg methylprednisolone I.M. the night before and morning of PTCA, and prednisone 60 mg p.o. Q.D. for 1 week post-PTCA)
Study: 7013060
Drug: No steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroids (control group)
Study: 24025700
Drug: High-dose steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose steroids
Study: 16302558
Drug: Metronidazole 0.75%
Normalized name: METRONIDAZOLE 0.75% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 0.75% gel
Study: 16316969
Drug: IV amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV amiodarone (low dose)
Study: 16316969
Drug: IV amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV amiodarone (medium dose)
Study: 16316969
Drug: IV amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV amiodarone (all doses)
Study: 1914758
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dose antacid (magaldrate) 88 mmol/day, given in three divided doses (10 ml after breakfast and lunch, 20 ml at bedtime) for eight weeks
Study: 1914758
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg/day, given in two divided doses (400 mg after breakfast and 400 mg at bedtime) for eight weeks
Study: 1914758
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dose antacid (magaldrate) 88 mmol/day, given in two schedules for four weeks
Study: 1914758
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg/day, given in two divided doses for four weeks
Study: 6136936
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg temazepam
Study: 1967533
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg temazepam
Study: 21751435
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of ropivacaine 0.5%
Study: 15814754
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of ropivacaine 0.5%
Study: 16707408
Drug: Montelukast 4-mg
Normalized name: montelukast 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4-mg oral granules
Study: 15504180
Drug: Methylprednisolone 125
Normalized name: methylprednisolone 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 125 mg i.v.
Study: 15504180
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg i.v. (active control)
Study: 9261520
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m2 (30 min IV infusion on days 1, 8, 15 of a 28-day cycle)
Study: 9587343
Drug: Full-dose Klean
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose Klean Prep
Study: 9587343
Drug: Half-dose Klean
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose Klean Prep
Study: 14482
Drug: oxazepam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxazepam (3 X 15 mg per day)
Study: 14482
Drug: oxypertine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxypertine (3 X 10 mg per day)
Study: 31934995
Drug: sampeginterferon beta
Normalized name: sampeginterferon beta-1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: sampeginterferon beta 1a 180 μg
Study: 31934995
Drug: sampeginterferon beta
Normalized name: sampeginterferon beta-1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: sampeginterferon beta 1a 240 μg
Study: 31934995
Drug: low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose interferon beta‐1a (LIB) 30 μg
Study: 22082677
Drug: Prophylactic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic heparin anticoagulation
Study: 27296126
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (AP)
Study: 29563781
Drug: Roflumilast 250
Normalized name: ROFLUMILAST 250MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 250 µg once daily (OD) followed by 500 µg OD for 8 weeks
Study: 29563781
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 µg every other day (EOD) followed by 500 µg OD for 8 weeks
Study: 29563781
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 µg once daily (OD) for 8 weeks
Study: 25595565
Drug: Allopurinol 100
Normalized name: allopurinol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 100 mg/d
Study: 24293994
Drug: Usual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual therapy (Control)
Study: 25400252
Drug: Allopurinol treatment
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol treatment
Study: 8792761
Drug: Triiodothyronine augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triiodothyronine augmentation
Study: 21209073
Drug: Intramyocardial bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial bone marrow cell injection
Study: 17728426
Drug: Aripiprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15 mg/day for the first 4 weeks, then 30 mg/day for the following 4 weeks)
Study: 2574766
Drug: Oxpentifylline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxpentifylline (500 mg over 4 h) after 100 ng endotoxin injection
Study: 2574766
Drug: Control (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (100 ng endotoxin injection without oxpentifylline)
Study: 1183792
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Heparin (Liquemin Roche) subcutaneously, 5000 units 2 hours pre-operatively and every 12 hours until the eighth post-operative day
Study: 1183792
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Heparin
Study: 1183792
Drug: Oral anti-coagulants
Normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-coagulants (Sintrom)
Study: 26156625
Drug: Rosuvastatin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (2.5 mg)
Study: 26156625
Drug: Pitavastatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (1 or 2 mg)
Study: 21971374
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg
Study: 18452434
Drug: Cream containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream containing retinol, lactose and glycolic acid applied twice daily for 12 weeks
Study: 18452434
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied twice daily for 12 weeks
Study: 16670692
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets twice daily for 6 months)
Study: 11680668
Drug: Control (Heparin)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (Heparin)
Study: 7964961
Drug: Conventional-dose alizapride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose alizapride (day 1, 100 mg i.v. and 4 x 50 mg orally; days 2 through 6, 4 x 50 mg orally)
Study: 7964961
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the dose of tropisetron (10 mg once daily)
Study: 23294549
Drug: DMPA-SC self-administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DMPA-SC self-administration
Study: 23294549
Drug: DMPA-SC self-administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DMPA-SC self-administration proficiency ratings
Study: 18327010
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg IM weekly for 12 weeks (group 2)
Study: 1735484
Drug: Parlodel (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parlodel (5 mg/d for first 15 days, then 10 mg/d for 1 month)
Study: 6371278
Drug: Dihydroergotamine mesylate,
Normalized name: Dihydroergotamine Mesylate, 4 mg/mL nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine mesylate, 0.5 mg, plus heparin sodium, 5,000 IU
Study: 6371278
Drug: Dihydroergotamine mesylate,
Normalized name: Dihydroergotamine Mesylate, 4 mg/mL nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine mesylate, 0.5 mg, plus heparin sodium, 2,500 IU
Study: 6371278
Drug: Heparin sodium,
Normalized name: heparin sodium, bovine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin sodium, 5,000 IU alone
Study: 31206083
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of zinc sulfate daily for 14 days
Study: 25007690
Drug: Epidural butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural butorphanol 0.04 mg/kg
Study: 25007690
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 0.06 mg/kg
Study: 22748873
Drug: Degarelix 240
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix 240 mg for 1 month followed by monthly maintenance doses of 80 or 160 mg
Study: 20131032
Drug: Qianggan Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianggan Capsule (QGC)
Study: 20131032
Drug: Polyene phosphatidylcholine
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyene phosphatidylcholine capsule (PPC)
Study: 17418289
Drug: Early abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early abciximab administration (in the emergency room)
Study: 16271912
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg daily (n = 120)
Study: 16271912
Drug: Naproxen 750
Normalized name: naproxen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 750 mg daily and Lansoprazole 30 mg daily (n = 122)